Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 285

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 285
---
DA of comparable companies in the genomics, artificial intelligence, healthcare data, diagnostics and digital healthcare sectors from various stages in development, including early stage, growth and mature companies, that were listed on either NYSE or Nasdaq with market capitalizations ranging from approximately $20 million to over $10 billion. These comparable companies were chosen due to the fact that they operate in one or more of the multiple core competencies or proposed areas of expansion of OmnigenicsAI’s business (genetic sequencing, microbiome analysis and artificial intelligence). As no company is a direct comparison to OmnigenicsAI’s product offering, companies across these multiple industries were evaluated to prepare a holistic comparison base. This was the only selection criteria for the comparable company analysis; companies were not selected (or excluded) based on other factors (such as, geographic market or location, or financial and operating metrics such as revenues, market capitalization, or other criteria) in order to include a broad data set of all potentially relevant comparable companies; •the comparable companies and the relevant financial information considered is set forth below:

| Company Name                            |     | Symbol        |     |      Equity 
 Value(1)(2) |   |     |       2023 
 Revenue(1) |     | 2023      
 EBITDA(1) |   |
| Genomics Companies                      |     |               |     |             |   |     |            |     |           |   |
| Intellia Therapeutics, Inc.             |     | NASDAQ:NTLA   |     |       1,859 |   |     |         36 |     | (506      | ) |
| 10x Genomics, Inc.                      |     | NASDAQ:TXG    |     |       4,297 |   |     |        619 |     | (159      | ) |
| uniQure N.V.                            |     | NASDAQ:QURE   |     |         159 |   |     |         16 |     | (255      | ) |
| Blueprint Medicines Corporation         |     | NASDAQ:BPMC   |     |       5,555 |   |     |        249 |     | (475      | ) |
| CRISPR Therapeutics AG                  |     | NASDAQ:CRSP   |     |       4,546 |   |     |        371 |     | (203      | ) |
| Krystal Biotech, Inc.